On April 9, 2024 Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, reported that it will participate in four investor conferences in the second quarter of 2024 (Press release, Allogene, APR 9, 2024, View Source [SID1234641921]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Canaccord Genuity Horizons in Oncology Virtual Conference
Monday, April 15, 2024
12:00pm PT/3:00pm ET

JPM Securities Life Sciences Conference
Tuesday, May 14, 2024
6:00am PT/9:00am ET

2024 RBC Capital Markets Global Healthcare Conference
Wednesday, May 15, 2024
8:00am PT/11:00am ET

Goldman Sachs 45th Annual Healthcare Conference
Tuesday, June 11, 2024
5:40am PT/8:40am ET

Any available webcasts will be posted to the Company’s website at www.allogene.com under the Investors tab in the News and Events section. Following a live webcast, a replay will be available on the Company’s website for approximately 30 days.